Silvan Turkcan
Stock Analyst at Citizens
(1.92)
# 3,193
Out of 5,241 analysts
10
Total ratings
55.56%
Success rate
2.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Silvan Turkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Therapeutics | Downgrades: Market Perform | n/a | $1.72 | - | 1 | May 8, 2026 | |
| CELC Celcuity | Maintains: Market Outperform | $150 → $160 | $137.68 | +16.21% | 2 | May 4, 2026 | |
| RLAY Relay Therapeutics | Maintains: Market Outperform | $17 → $19 | $12.20 | +55.74% | 2 | Apr 28, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Market Outperform | $28 → $30 | $13.67 | +119.46% | 2 | Apr 28, 2026 | |
| HURA TuHURA Biosciences | Initiates: Market Outperform | $9 | $2.31 | +289.61% | 1 | Apr 27, 2026 | |
| CLLS Cellectis | Reiterates: Market Outperform | $8 | $3.97 | +101.51% | 1 | Apr 14, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Market Outperform | $86 → $80 | $48.41 | +65.26% | 1 | Jan 30, 2026 |
enGene Therapeutics
May 8, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $1.72
Upside: -
Celcuity
May 4, 2026
Maintains: Market Outperform
Price Target: $150 → $160
Current: $137.68
Upside: +16.21%
Relay Therapeutics
Apr 28, 2026
Maintains: Market Outperform
Price Target: $17 → $19
Current: $12.20
Upside: +55.74%
Intellia Therapeutics
Apr 28, 2026
Maintains: Market Outperform
Price Target: $28 → $30
Current: $13.67
Upside: +119.46%
TuHURA Biosciences
Apr 27, 2026
Initiates: Market Outperform
Price Target: $9
Current: $2.31
Upside: +289.61%
Cellectis
Apr 14, 2026
Reiterates: Market Outperform
Price Target: $8
Current: $3.97
Upside: +101.51%
CRISPR Therapeutics AG
Jan 30, 2026
Maintains: Market Outperform
Price Target: $86 → $80
Current: $48.41
Upside: +65.26%